TrialNature medicine2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Lin Shen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.